Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase III, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician?s Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia.
Study Type: Treatment
Phase: III
NCTID: NCT04778397
Principal Investigator:
Jesus Gonzalez Lugo
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia AML: A MyeloMATCH Treatment Trial
Study Type: Treatment
Phase: II
NCTID: NCT06317649
Principal Investigator:
Jesus Gonzalez Lugo
A Phase III, Open-Label, Randomized Study of Sonrotoclax BGB-11417 Plus Zanubrutinib BGB-3111 Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Study Type: Treatment
Phase: III
NCTID: NCT06073821
Principal Investigator:
Marc Hoffmann
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States THRIVE
A First-in-Human FIH, Phase 1, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Orally Administered GLB-001 in Patients with Refractory or Relapsed Acute Myeloid Leukemia R/R AML or Refractory or Relapsed Higher-risk Myelodysplastic Syndromes R/R HR-MDS
Study Type: Treatment
Phase: I
NCTID: NCT06146257
Principal Investigator:
Jesus Gonzalez Lugo
A Phase II Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway?Mutant Acute Lymphoblastic Leukemia
Study Type: Treatment
Phase: II
NCTID: NCT02723994
Principal Investigator:
Kevin Ginn
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Study Type: Treatment
Phase: III
NCTID: NCT02521493
Principal Investigator:
Keith August
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia CLL
Study Type: Treatment
Phase: III
NCTID: NCT03701282
Principal Investigator:
Marc Hoffmann
A Phase IB/IIA, Open-Label Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of Fosciclopirox Alone And In Combination With Cytarabine In Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase II study of SNDX-5613 in combination with chemotherapy for patients with relapsed or refractory KMT2A-rearranged infant leukemia
Study Type: Treatment
Phase: II
NCTID: NCT05761171
Principal Investigator:
Kevin Ginn